SEATTLE, Sept. 13 /PRNewswire-FirstCall/ -- ZymoGenetics, Inc. (Nasdaq: ZGEN - News) announced today that company executives will review results from the rhThrombin Phase 3 clinical trial at an analyst and investor meeting to be held on Monday, September 18 at 10:00 a.m. Eastern Time at the Grand Hyatt New York in the Chrysler Boardroom in New York City.
